Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

STATUS

Recruiting
End date

Dec 31, 2029
participants needed

56
sponsor

Christian Buske

Send

Updated on 21 April 2022

See if I qualify

ct scan

platelet count

remission

rituximab

measurable disease

interferon

cytopenia

neutrophil count

tositumomab

chlorambucil

gastric malt lymphoma

splenic marginal zone lymphoma

Summary

For marginal zone lymphoma (MZL) Rituximab in combination with conventional chemotherapy is widely used for those patients who fail local therapy or do not qualify for such. Depending on the MZL subtype Rituximab/chemotherapy is able to induce in part long remissions, but do not prevent relapse later on. In addition, chemotherapy associated toxicity is often problematic in MZL patients, who are mostly of advanced age. Thus, chemotherapy - free approaches are highly attractive for this patient group. Rituximab single agent is a widely used chemotherapy - free approach in MZL, but was significantly inferior compared to Rituximab/chlorambucil in a large randomized prospective clinical trial in treatment naïve MZL with a CR rate of 56 % vs. 80%, respectively (P<0.001). Thus, it is the major aim to develop chemotherapy - free approaches for MZL, which approach efficacy of Rituximab/chemotherapy combinations, but avoid chemotherapy associated toxicities. This in particular important in MZL as many physicians are reluctant to treat these often elderly patients with more intense treatments and prefer single agent therapies in these very often well and long responding lymphoma subtype. The PI3K inhibitor Copanlisib has shown high clinical activity in indolent B - cell lymphomas among them MZL. Based on these observations it is the aim of this study to test the toxicity and efficacy of Copanlisib in combination with the anti-CD20 antibody Rituximab in patients with newly diagnosed or relapsed MZL in need of treatment, who are not eligible or failed local therapy, following the assumption that this novel chemotherapy - free combination is significantly more effective than Rituximab single agent therapy and at least as efficient as Rituximab/chemotherapy, but avoids chemotherapy - related toxicity.

Description

The objective of the trial is to test the efficacy and toxicity of the treatment of Copanlisib/Rituximab in patients with MZL in need of treatment, who have failed or are not eligible for local therapy or relapsed after local or systemic therapy. For efficacy the rate of complete remissions (according to the GELA criteria for gastric MALT or to the Cheson 2007 criteria for non-gastric extranodal, nodal and splenic MZL) after induction therapy will be primarily analysed. For toxicity treatment associated adverse events, quality of life and cumulative incidence of secondary malignancies will be documented.

Details

Condition	Marginal Zone Lymphoma
Treatment	Rituximab, Copanlisib
Clinical Study Identifier	NCT03474744
Sponsor	Christian Buske
Last Modified on	21 April 2022

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Patients must meet all of the following inclusion criteria to be eligible for participation
	in this study
	Confirmed CD20 positive MALT Lymphoma de novo or relapsed following or being not
	eligible for local therapy (including surgery, radiotherapy) and antibiotics for H
	pylori-positive gastric lymphoma arisen at any extranodal site OR
	Confirmed CD20 positive de novo or relapsed splenic MZL following or not being
	eligible for local therapy (including surgery and antiviral therapy for Hepatitis C
	Virus) with symptomatic disease OR
	Confirmed CD20 positive de novo or relapsed nodal MZL Tissue diagnostic procedures
	must be performed within 12 months prior to study entry and have to include
	diagnostics by a reference pathology center. Biopsy material from an excisional or
	For nodal MZL and extragastric MALT lymphoma
	core biopsy must be submitted for retrospective central confirmation. Tissue samples
	dated > 12 months prior to informed consent can be accepted only if tissue material is
	For SMZL
	available for retrospective confirmation, if there is no clinical indication for
	transformation of disease, and if the request for additional biopsy would be unethical
	treatment of the patient
	In patients with splenic MZL without splenic tissue available for histologic review, the
	At least one of the following criteria must be met
	diagnosis may be confirmed by the presence of splenomegaly and typical morphologic and
	Bulky progressive or painful splenomegaly
	immunophenotypic findings in the blood and bone marrow. Bone marrow (acceptable up to 12
	weeks before start of treatment) must be submitted for retrospective central confirmation
	Patients in need of treatment: For patients with symptomatic splenic, nodal, or
	non-gastric extranodal MZL disease that is de novo or has relapsed following local therapy
	For gastric MALT lymphoma
	(i.e., surgery or radiotherapy) and requires therapy, as assessed by the investigator
	At least one bi-dimensionally measurable lesion (≥ 1.5 cm in its largest dimension by CT
	scan or MRI). Please refer to Appendix C
	Inclusion is possible for patients with
	For splenic MZL, an enlarged spleen on CT scan and lymphoma cell infiltration has to be
	seen in bone marrow and/or peripheral blood. Please refer also to Appendix E
	Others
	Age >= 18 years
	Life expectancy >3 months
	one of the following symptomatic/progressive cytopenias: Hb < 10 g/dL, or Plat <
	000 /µL, or neutropenia < 1000/µL, whatever the reason (autoimmune or hypersplenism
	or bone marrow infiltration)
	ASAT (SGOT): <= 3 times the upper limit of institutional laboratory normal value
	SMZL with concomitant hepatitis C infection which has not responded to or has relapsed
	ALAT (SGPT): <= 3 times the upper limit of institutional laboratory normal value
	after Interferon and/or Ribavirin and/or direct antiviral agents (patients positive
	for HCV antibody are eligible only if PCR is negative for HCV RNA)
	splenectomised patients with rapidly raising lymphocyte counts, development of
	Negative HIV antibody
	lymphadenopathy or involvement of extranodal sites if not being eligible for local
	therapy
	For gastric MALT lymphoma, the clinical evidence of the MZL as seen by gastroendoscopy is
	sufficient. There is no need to show a measurable lesion by CT scan or MRI. Please refer to
	Appendix D
	H. pylori-negative disease de novo or following or being not eligible for local
	therapy (i.e., surgery, radiotherapy or antibiotics) or after systemic therapy
	H. pylori-positive disease that has remained stable, progressed, or relapsed following
	antibiotic therapy
	Baseline platelet Count >= 50 x 109/L (if not due to BM infiltration by the lymphoma)
	absolute neutrophil Count >= 0.75 x 109/L
	Meet the following pretreatment laboratory criteria at the Screening visit conducted
	within 28 days of study enrollment (unless due to underlying lymphoma)
	Total Bilirubin: <= 2 mg/dL or 2 times the upper limit of institutional
	laboratory normal value, unless clearly related to the disease (except if due to
	Gilbert's syndrome)
	GFR ≥ 40 mL/min/1.73 m²
	Positive test results for chronic HBV infection (defined as positive HBsAg serology)
	patients with occult or prior HBV infection (defined as negative HBsAg and positive
	total HBcAb) may be included if HBV DNA is undetectable, provided that they are
	willing to undergo monthly DNA testing. Patients who have protective titers of HBsAb
	after vaccination or prior but cured hepatitis B are eligible
	Positive test results for hepatitis C (hepatitis C virus [HCV] antibody serology
	testing): patients positive for HCV antibody are eligible only if PCR is negative for
	HCV RNA
	Pregnancy β-HCG negative. For women of child-bearing potential only (i.e. fertile
	following menarche and until becoming post-menopausal unless permanently sterile
	Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and
	bilateral oophorectomy); serum or urine β-HCG must be negative during screening and at
	study enrolment visit
	Premenopausal fertile females must agree to use a highly effective method of birth
	control for the duration of the therapy up to 12 months after end of therapy. A highly
	effective method of birth control is defined as those which result in a low failure
	rate (i.e. less than 1% per year) when used consistently and correctly such as
	combined (estrogen and progestogen containing) hormonal contraception associated with
	inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal
	contraception associated with inhibition of ovulation (oral, injectable or
	implantable), intrauterine device (IUD), intrauterine hormone-releasing system ( IUS)
	bilateral tubal occlusion, vasectomised partner or sexual abstinence. Contraception
	and pregnancy testing are required according the CTFG recommendations
	(<http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/>
	_09_HMA_CTFG_Contraception.pdf)
	Men must agree not to father a child for the duration of therapy and 6 months after
	(use of a condom) and must agree to advice a female partner to use a highly effective
	method of birth control
	Willingness and ability to comply with scheduled visits, drug administration plan
	imaging studies, laboratory tests, other study procedures, and study restrictions
	Evidence of a personally signed informed consent indicating that the subject is aware
	of the neoplastic nature of the disease and has been informed of the procedures to be
	followed, the experimental nature of the therapy, alternatives, potential benefits
	possible side effects, potential risks and discomforts, and other pertinent aspects of
	study participation
Exclusion Criteria
	The presence of any of the following will exclude a subject from enrolment
	Ongoing alcohol or drug addiction
	Breastfeeding or pregnancy
	Prior treatment with Copanlisib
	Congestive heart failure > New York Heart Association (NYHA) class 2
	Myocardial infarction less than 6 months before start of test drug
	Uncontrolled arterial hypertension despite optimal medical management
	HbA1c>8.5%
	Vaccination with a live vaccine within 28 days prior to start of therapy
	Non-healing wound, ulcer, or bone fracture
	ECOG performance status ≥ 2
	History of a non-lymphoid malignancy except for the following: adequately treated
	local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ
	superficial bladder cancer, asymptomatic prostate cancer without known metastatic
	disease and with no requirement for therapy or requiring only hormonal therapy and
	with normal prostate specific antigen for ≥1 year prior to study enrollment visit
	other Stage 1 or 2 cancer treated with a curative intent and currently in complete
	remission, for ≥3 years
	Central nervous system lymphoma, leptomeningeal lymphoma, or histologic evidence of
	transformation to a high-grade or diffuse large B-cell lymphoma
	Ongoing immunosuppressive therapy including corticosteroids (exception < 4 weeks
	administered at a dose equivalent to ≤ 40 mg/day prednisone is allowed)
	Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of
	study enrolment visit
	Ongoing drug-induced liver injury, chronic active hepatitis B (HBV), alcoholic liver
	disease, non-alcoholic steatohepatitis, primary biliary cholangitis, extrahepatic
	obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension
	Treatment with any other investigational agent within 30 days or within 5 x the
	half-life (t1/2) of the investigational product, whichever is longer, or participating
	in another trial within 30 days prior to entering this study
	Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3
	months)
	Prior or ongoing clinically significant illness, medical condition, surgical history
	physical finding, electrocardiogram (ECG) finding, or laboratory abnormality that, in
	the investigator's opinion, could adversely affect the safety of the subject or impair
	the assessment of study results
	History of anaphylaxis in association with previous administration of monoclonal
	antibodies
	Arterial or venous thrombotic or embolic events such as cerebrovascular accident
	(including transient ischemic attacks), deep vein thrombosis or pulmonary embolism
	within 3 months before the start of study medication
	History or concurrent interstitial lung disease of any severity and/or severely
	impaired lung function (as judged by the investigator)

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

0/250

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

gastric malt lymphoma

splenic marginal zone lymphoma

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Edit Delete

Added by •

•

Private

Edit Delete

Reply by • • Private

Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

Enter the passcode

The passcode will expire in None.

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients